Retifanlimab is a monoclonal antibody commercialized by Incyte, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 37 clinical trials, of which 4 were completed, 31 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Retifanlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Retifanlimab is expected to reach an annual total of $80 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Retifanlimab (MGA-012) is under development for the treatment of solid tumors including retroperitoneal sarcoma, newly-diagnosed glioblastoma multiforme, muscle-invasive urothelial carcinoma, well differentiated liposarcoma and dedifferentiated liposarcoma, advanced penile squamous cell carcinoma, recurrent and metastatic squamous cell carcinoma of the head and neck including oropharyngeal cancer, oral cavity cancer, hypopharynx cancer, and laryngeal cancer, metastatic melanoma, anal cancer, recurrent glioblastoma multiforme, metastatic non-small cell lung cancer, relapsed or refractory acute myeloid leukemia, metastatic urothelial cancer, metastatic renal cell carcinoma, cervical cancer, metastatic adenosquamous carcinoma of the pancreas, esophageal squamous cell carcinoma, metastatic triple negative breast cancer, endometrial cancer, HER2 positive gastric cancer, gastroesophageal junction adenocarcinoma and soft tissue sarcoma. The therapeutic candidate is administered as an intravenous infusion. It is a monospecific, bivalent and it’s half life last from days to weeks. It is based on Fc Optimization platform technology. The therapeutic candidate acts by targeting Programmed Cell Death Protein 1. It was also under development for hematological malignancies, squamous carcinoma of the anal canal and merkel cell carcinoma.
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
The company reported revenues of (US Dollars) US$3,394.6 million for the fiscal year ended December 2022 (FY2022), an increase of 13.7% over FY2021. The operating profit of the company was US$579.4 million in FY2022, compared to an operating profit of US$585.8 million in FY2021. The net profit of the company was US$340.7 million in FY2022, compared to a net profit of US$948.6 million in FY2021.
For a complete picture of Retifanlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.